Sepragen.com

Home | Contact Us 


Online Catalog


View our online catalog.
For further information or for a quotation, call 1-510-475-0650 or email us at sales@sepragen.com.



How Can We Help You?
Click here to contact us!

 



Sepragen Announces the Launch of the QuantaSep 5000

SAN LEANDRO, Calif.--(BW HealthWire)--June 5, 2002--Sepragen Corporation (OTC BB: SPGNA - News), a provider of patented technology and equipment for purification needs in the biotech and nutraceutical industries, today announced the launch of the QuantaSep 5000 Chromatography System. The QuantaSep 5000 is a totally automated system that enables a biotech company to run at flow rates of 5 liters per minute and produce 10 grams to 100 grams of product for clinical trials and manufacturing. The system is a direct scale-up of the QuantaSep bench-scale purification systems, which currently range in size from 100 to 1800 mls per minute.

Said Mr. Vinit Saxena, Sepragen's CEO, "The QuantaSep 5000 allows a biotech company to add productive capacity at 25% of the footprint requirement of currently available systems. This enables a company to better utilize its existing facilities, and ramp up manufacturing capacity without investment of time and resources in new facility construction and approval. The state-of-the-art graphical dashboard enables easy operation with a high level of reliability along with automated FDA compliant report generation, even by lesser skilled production staff." Continued Mr. Saxena, "Our continued focus on using our proprietary technologies to solve urgent manufacturing and scale-up issues by providing the industry with a 4-fold productive capacity advantage in space and manpower utilization is receiving notice. Major companies, such as Schering-Plough, Berlex, Human Genome Sciences and others have already adopted the QuantaSep platform for development and scale-up and others are expected to follow."

Sepragen is a leading supplier of separation process technology, equipment and consumables to the biotechnology industry. In addition to its biotech drug separation business, the Company has developed patented applications that provide large market opportunities in the food and beverage industry, including debittering citrus juices, extracting isoflavone (plant estrogen) from soy as well as extracting proteins from whey. The Company holds over 14 issued patents relating to its core technology.

Return to News Archives main page



The statements in this release that relate to future events or performance, statements about growth, future regulatory clearances, levels of sales and market size and future manufacturing capacity and efficiencies are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to the development of markets for and commercial acceptance of the company's products and services, the availability of components, competitors' product introductions and other risks identified in the company's SEC filings. Actual results may differ from those described in these forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.


Company | Products | News and Events | Contact Us | Terms and Conditions | Privacy Policy © 2018 Sepragen Corporation. All rights reserved. (510) 475-0650